Pfizer has preliminary data showing its experimental drug for atopic dermatitis beat a blockbuster drug from Regeneron Pharmaceuticals in a head-to-head clinical trial. But the future of that drug and others might depend more on an FDA review of safety data for medicines in this class of so-called JAK inhibitors.
Amgen is paying Kyowa Kirin $400 million to share in the development of a drug that could offer a new approach to treating atopic dermatitis, a form of eczema. The deal comes months after Japan-based Kyowa Kirin reported positive preliminary Phase 2 data for its antibody.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
The company is developing abrocitinib, a JAK1 inhibitor, for the disease. Incyte is also developing a topical formulation of its JAK2 inhibitor for atopic dermatitis.
The companies also reported a European dermatitis approval and successful topline results from a Phase III study of the drug, Dupixent.